{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:54:53Z","timestamp":1790895293957,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"DOI":"10.1186\/s13000-026-01803-w","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T12:56:14Z","timestamp":1784984174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Refining prostate cancer diagnosis: correlative analysis of Gleason scores and immunohistochemical markers"],"prefix":"10.1186","volume":"21","author":[{"given":"Hongfeng","family":"Ao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6176-5547","authenticated-orcid":false,"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"issue":"1","key":"1803_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pathol.2020.10.003","volume":"53","author":"T Vlajnic","year":"2021","unstructured":"Vlajnic T, Bubendorf L. Molecular pathology of prostate cancer: a practical approach. Pathology Jan. 2021;53(1):36\u201343. https:\/\/doi.org\/10.1016\/j.pathol.2020.10.003.","journal-title":"Pathology Jan"},{"issue":"1","key":"1803_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12935-024-03231-6","volume":"5","author":"V Pecci","year":"2024","unstructured":"Pecci V, Troisi F, Aiello A, et al. Targeting of H19\/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer. Cancer Cell Int Feb. 2024;5(1):56. https:\/\/doi.org\/10.1186\/s12935-024-03231-6.","journal-title":"Cancer Cell Int Feb"},{"key":"1803_CR3","doi-asserted-by":"publisher","unstructured":"Kie\u0142b P, Kowalczyk K, Gurwin A, et al. Novel histopathological biomarkers in prostate cancer: implications and perspectives. Biomedicines. 2023;26(6). https:\/\/doi.org\/10.3390\/biomedicines11061552.","DOI":"10.3390\/biomedicines11061552"},{"key":"1803_CR4","doi-asserted-by":"publisher","unstructured":"Fiorentino V, Martini M, Dell\u2019Aquila M, et al. Histopathological ratios to predict Gleason score agreement between biopsy and radical prostatectomy. Diagnostics (Basel). 2020;23(1). https:\/\/doi.org\/10.3390\/diagnostics11010010.","DOI":"10.3390\/diagnostics11010010"},{"key":"1803_CR5","doi-asserted-by":"publisher","first-page":"156040","DOI":"10.1016\/j.prp.2025.156040","volume":"271","author":"V Fiorentino","year":"2025","unstructured":"Fiorentino V, Pepe L, Zuccal\u00e0 V, et al. Gleason score down and upgrading at radical prostatectomy in targeted vs. systematic prostate biopsy: Findings from an institutional cohort. Pathol Res Pract Jul. 2025;271:156040. https:\/\/doi.org\/10.1016\/j.prp.2025.156040.","journal-title":"Pathol Res Pract Jul"},{"issue":"4","key":"1803_CR6","doi-asserted-by":"publisher","first-page":"12992","DOI":"10.4081\/aiua.2024.12992","volume":"11","author":"P Pepe","year":"2024","unstructured":"Pepe P, Pepe L, Fiorentino V, Curduman M, Fraggetta F. Multiparametric MRI targeted prostate biopsy: When omit systematic biopsy? Arch Ital Urol Androl Nov. 2024;11(4):12992. https:\/\/doi.org\/10.4081\/aiua.2024.12992.","journal-title":"Arch Ital Urol Androl Nov"},{"key":"1803_CR7","doi-asserted-by":"publisher","unstructured":"Pepe P, Pepe L, Fiorentino V, Curduman M, Pennisi M, Fraggetta F. PSMA PET\/CT accuracy in diagnosing prostate cancer nodes metastases. In vivo (Athens, Greece). 2024;38(6):2880\u20135. https:\/\/doi.org\/10.21873\/invivo.13769.","DOI":"10.21873\/invivo.13769"},{"issue":"2","key":"1803_CR8","doi-asserted-by":"publisher","first-page":"11322","DOI":"10.4081\/aiua.2023.11322","volume":"22","author":"P Pepe","year":"2023","unstructured":"Pepe P, Pepe L, Tamburo M, et al. 68Ga-PSMA PET\/CT evaluation in men enrolled in prostate cancer Active Surveillance. Arch Ital Urol Androl May. 2023;22(2):11322. https:\/\/doi.org\/10.4081\/aiua.2023.11322.","journal-title":"Arch Ital Urol Androl May"},{"key":"1803_CR9","doi-asserted-by":"publisher","first-page":"155916","DOI":"10.1016\/j.prp.2025.155916","volume":"269","author":"V Fiorentino","year":"2025","unstructured":"Fiorentino V, Pepe L, Pizzimenti C, et al. PD-L1 expression in prostate cancer and Gleason Grade Group: Is there any relationship? Findings from a multi-institutional cohort. Pathol Res Pract May. 2025;269:155916. https:\/\/doi.org\/10.1016\/j.prp.2025.155916.","journal-title":"Pathol Res Pract May"},{"key":"1803_CR10","doi-asserted-by":"publisher","unstructured":"Grammatikopoulou MG, et al. Dietary factors and supplements influencing prostate specific-antigen (PSA) concentrations in men with prostate cancer and increased cancer risk: an evidence analysis review based on randomized controlled trials. Nutrients. 2020;12(10). https:\/\/doi.org\/10.3390\/nu12102985.","DOI":"10.3390\/nu12102985"},{"key":"1803_CR11","doi-asserted-by":"publisher","unstructured":"Merriel SWD, et al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022;20(1):54. https:\/\/doi.org\/10.1186\/s12916-021-02230-y.","DOI":"10.1186\/s12916-021-02230-y"},{"key":"1803_CR12","doi-asserted-by":"publisher","unstructured":"Estalilla OC, et al. 5'3' exonuclease-based real-time PCR assays for detecting the t(14;18)(q32;21): a survey of 162 malignant lymphomas and reactive specimens. Mod Pathol. 2000;13(6):661\u20136. https:\/\/doi.org\/10.1038\/modpathol.3880116.","DOI":"10.1038\/modpathol.3880116"},{"key":"1803_CR13","doi-asserted-by":"publisher","unstructured":"In Brief. Nat Rev Cancer. 2004;4(4):247. https:\/\/doi.org\/10.1038\/nrc1333.","DOI":"10.1038\/nrc1333"},{"key":"1803_CR14","doi-asserted-by":"publisher","unstructured":"Brassell SA, et al. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology. 2005;66(6):1229\u201333. https:\/\/doi.org\/10.1016\/j.urology.2005.06.106.","DOI":"10.1016\/j.urology.2005.06.106"},{"key":"1803_CR15","doi-asserted-by":"publisher","unstructured":"Tait CR, Dodwell D, Horgan K. Do metastases metastasize? J Pathol. 2004;203(1):515\u20138. https:\/\/doi.org\/10.1002\/path.1544.","DOI":"10.1002\/path.1544"},{"key":"1803_CR16","doi-asserted-by":"publisher","unstructured":"Cormier EG, et al. Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc Natl Acad Sci U S A. 2000;97(11):5762\u20137. https:\/\/doi.org\/10.1073\/pnas.97.11.5762.","DOI":"10.1073\/pnas.97.11.5762"},{"key":"1803_CR17","doi-asserted-by":"publisher","unstructured":"Alibhai SMH, et al. The association between patient age and prostate cancer stage and grade at diagnosis. BJU Int. 2004;94(3):303\u20136. https:\/\/doi.org\/10.1111\/j.1464-410X.2004.04883.x.","DOI":"10.1111\/j.1464-410X.2004.04883.x"},{"key":"1803_CR18","doi-asserted-by":"publisher","unstructured":"Kong X, et al. Hematopoietic cell kinase (HCK) is essential for NLRP3 inflammasome activation and lipopolysaccharide-induced inflammatory response in vivo. Front Pharmacol. 2020;11:581011. https:\/\/doi.org\/10.3389\/fphar.2020.581011.","DOI":"10.3389\/fphar.2020.581011"},{"key":"1803_CR19","doi-asserted-by":"publisher","unstructured":"Caner A, Asik E, Ozpolat B. SRC Signaling in Cancer and Tumor Microenvironment. In: Birbrair A, editor. Tumor Microenvironment: Signaling Pathways \u2013 Part B. Cham: Springer International Publishing; 2021. p. 57\u201371. https:\/\/doi.org\/10.1007\/978-3-030-47189-7_4.","DOI":"10.1007\/978-3-030-47189-7_4"},{"key":"1803_CR20","doi-asserted-by":"publisher","unstructured":"Raut R, et al. Chapter 17 - Src kinase: an attractive therapeutic target for prostate cancer. In: Hassan MI, Noor S, editors. Protein Kinase Inhibitors. Academic Press; 2022. p. 479\u2013503. https:\/\/doi.org\/10.1016\/B978-0-323-91287-7.00029-6.","DOI":"10.1016\/B978-0-323-91287-7.00029-6"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-026-01803-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-026-01803-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-026-01803-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:02:52Z","timestamp":1790892172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13000-026-01803-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1803"],"URL":"https:\/\/doi.org\/10.1186\/s13000-026-01803-w","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This was a retrospective cohort study conducted at Shanghai Jiao Tong University Affiliated Sixth People\u2019s Hospital, a tertiary care academic medical center (No. Not assigned, our institutional ethics committee has formally approved this study and confirmed that our institution does not issue dedicated ethics approval numbers for retrospective, observational studies of this nature (which uses de-identified archived clinical samples with no direct patient intervention).All research conducted on humans and human data\/material in this study adhered to the Helsinki Declaration. Given its retrospective design and use of anonymized archival pathology data, the requirement for informed consent was waived by the ethics committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"71"}}